{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:01:46Z","timestamp":1772118106036,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In two 24\u2010week migraine prevention studies in Japan, erenumab was associated with significantly greater reductions in migraine frequency versus placebo over Weeks 13\u201324 (primary endpoint). This post hoc analysis evaluated the onset of efficacy within the first 4\u00a0weeks after the initiation of erenumab from the 24\u2010week double\u2010blind periods of these studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Placebo\u2010adjusted differences in least squares mean (LSM) change from baseline in weekly migraine days (WMD) were assessed weekly in each study and by migraine type (episodic (EM]\/chronic [CM]) (Study 20170609).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 407 patients from Study 20120309 (70\u00a0mg: N\u00a0=\u00a0135; 140\u00a0mg: N\u00a0=\u00a0136; placebo: N\u00a0=\u00a0136) and 261 patients from Study 20170609 ([EM] 70\u00a0mg: N\u00a0=\u00a078; placebo: N\u00a0=\u00a081; [CM] 70\u00a0mg: N\u00a0=\u00a052; placebo: N\u00a0=\u00a050) were included. For Study 20120309, onset of efficacy was observed as early as Week 1 in favor of erenumab versus placebo. Placebo\u2010adjusted differences in LSM (95% confidence interval [CI]) change from baseline in WMD at Week 1 were \u22120.38 (\u22120.71 to \u22120.05;\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a0.022) and \u22120.49 (\u22120.82 to \u22120.16;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.004) in favor of erenumab 70 and 140\u00a0mg, respectively. For Study 20170609, significant placebo\u2010adjusted differences were observed with erenumab 70\u00a0mg at Week 1 in patients with EM (LSM [95% CI]: \u22120.55 [\u22120.97 to \u22120.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.012]), and at Week 2 in patients with CM (LSM [95% CI]: \u22120.81 [\u22121.53 to \u22120.09;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.028]) and for the overall population (LSM [95% CI]: \u22120.71 [\u22121.09 to \u22120.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.001]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erenumab treatment significantly reduced WMD compared with placebo. Onset of erenumab efficacy occurred as early as Week 1 in patients with migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.2526","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T15:34:59Z","timestamp":1645716899000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double\u2010blind, placebo\u2010controlled studies"],"prefix":"10.1002","volume":"12","author":[{"given":"Koichi","family":"Hirata","sequence":"first","affiliation":[{"name":"Department of Neurology Dokkyo Medical University  Tochigi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Neurology Tominaga Hospital  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Saitama International Headache Center  Saitama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Neurology Japanese Red Cross Shizuoka Hospital  Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[{"name":"Sendai Headache and Neurology Clinic  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Tatsuoka","sequence":"additional","affiliation":[{"name":"Department of Neurology Tatsuoka Neurology Clinic  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotaro","family":"Numachi","sequence":"additional","affiliation":[{"name":"Amgen K.K. Research &amp; Development  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Amgen K.K. Research &amp; Development  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Amgen Inc. Global Biostatistical Science  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc. Global Development  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel Paiva da Silva","family":"Lima","sequence":"additional","affiliation":[{"name":"Amgen Inc. Global Development  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Amgen Inc. Global Development  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Aimovig [prescribing information](2018). Amgen.https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/aimovig\/aimovig_pi_hcp_english.ashx."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13691"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419851855"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010017\u20100592\u20101"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.173.5.341"},{"key":"e_1_2_10_11_1","unstructured":"Pharmaceutical and Medical Devices Agency(2021). Aimovig subcutaneous 70 mg review report.https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210629001\/112292000_30300AMX00290000_A100_1.pdf."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010018\u20100923\u20106"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001186\u20103"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14138"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(17)30083\u20102"},{"key":"e_1_2_10_18_1","unstructured":"Topamax [prescribing information]. (2009). Janssen Pharmaceuticals Inc.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020505s061 020844s052lbl.pdf."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001111\u20108"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010019\u20101012\u20101"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010017\u20102183\u20106"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13654"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.2526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:01:29Z","timestamp":1692316889000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.2526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/brb3.2526"],"URL":"https:\/\/doi.org\/10.1002\/brb3.2526","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.2526\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2526\/v1\/decision1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"2021-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2526"}}